AstraZeneca Investor Day Presentation Deck

24 After almost a decade, the addition of Lynparza achieves a similar absolute rPFS improvement compared to the pivotal trial that established abiraterone as first-line SoC Median rPFS COU-AA-302¹ (2012) control abiraterone 8.2m 16.4m PROpel median rPFS Investigator assessment BICR HRRm Non-HRRm Dif. 8.2m 16.6m abiraterone 16.6m 13.9m 19.0m 16.4m abi 1. Mulders et al. N Engl J Med 2013; 368:138-148. Dif. = difference; NR = not reached; HR = hazard ratio. PROpel (2022) Lynparza + abiraterone 24.8m Lynparza + abiraterone 24.8m NR 24.1m 27.6m Dif. 8.2m HR 0.66 (0.54-0.81) 0.50 (0.34-0.73) 0.76 (0.60-0.97) 0.61 (0.49-0.74)

View entire presentation